Fully human anti-CD19 CAR-T cells

Fully human anti-CD19 CAR-T cells are an investigational autologous chimeric antigen receptor (CAR) T-cell therapy developed by Benjamin Tomlinson and researchers at University Hospitals Cleveland Medical Center. This therapy involves genetically engineering a patient's own T cells to express a CAR that targets the CD19 antigen, a protein widely expressed on the surface of B-cell lineage cells and most B-cell malignancies. The construct is distinguished by its use of a fully human single-chain variable fragment (scFv) binding domain, which is intended to reduce immunogenicity and potential rejection by the patient's immune system compared to traditional murine-derived binders (such as FMC63). The CAR construct also incorporates a 4-1BB (CD137) costimulatory domain and a CD3-zeta signaling domain to enhance T-cell activation, expansion, and persistence. It is currently being evaluated in Phase I clinical trials for the treatment of relapsed or refractory B-cell lymphoid malignancies, including non-Hodgkin lymphoma (NHL), acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL).

Other names

Human anti-CD19 CAR-T cellshuCART19huCART-19huCART 19